A Message to Guy “Can’t Git-R-Done” Chapman

Guy “Crapman” Chapman is a SkeptiCoward©

20131004-021044.jpg
I’m NOT “Astroturfwatch” you twit
——————————————————————
“Guy” blogged another one of “The Skeptics™” #Fails [1]

He has a blog full of essentially misinformation, disinformation, misdirection, and lies regarding Burzynski, but the gist of it is that so far he has demonstrated to the entire world that he is that “Guy”, that “Yellow-Back” Chap, man, who has NOT demonstrated that he has the “Grapefruits”, to answer for his actions [2-4]

He claims my blog is “full of essentially incoherent commentary,” yet he offers NO explanation as to why it is that since its inception 2/14/2013, the Didymus Judas Thomas’ Hipocritical Oath Blog has had 9,626 visitors

20131003-223812.jpg
Where’s your stats, Guy ?

Lets “review” his latest piece of propaganda and Dezinformatsiya, shall we ?
——————————————————————
“The FDA approved a phase 3 trial, therefore Burzynski’s antineoplastons definitely work”
——————————————————————
#fail [5]

“[T]he emphasis in Phase 2 is on EFFECTIVENESS

“Phase 3 studies begin if EVIDENCE of EFFECTIVENESS is shown in Phase 2″
——————————————————————
“The Lancet rejected publication of the sole paper known to have been sumbitted from the one completed phase 2 trial, therefore there is a global conspiracy to suppress Burzynski”
——————————————————————
#Fail [6]

Bob Blaskiewicz postulated during the Google+ Hangout on Saturday, that this is a generic, usual, normal course-of-business rejection letter

NO such example is on Al Gore’s Internet

Whose got one ?

20130930-164002.jpg
Even in a Tweet, everybody must include all caveats and the full body of knowledge with footnotes, or stand convicted of lying
——————————————————————
#FaiL

Do NOT post deceptive Twits:

20130928-192050.jpg

20130930-101722.jpg
#faIL

@SceptiGuy, on 5/25/2013, what did you NOT understand about her 5/23/2013 Cease and Desist Tweet ?

20131003-094026.jpg
A trial at a reputable cancer center once took several years to complete and publish, therefore failure to complete and publish a single trial in 40 years means nothing
——————————————————————
#FaiL

So, does this mean you wanted Burzynski to publish the phase 2 clinical trial final results before the trials were finished ?
——————————————————————
“Failure to participate on a partisan blog means you refuse to debate”
——————————————————————
#FAil [7]

Is this just another one of “The Skeptics™” Red Herring’s you like to use ?

The About page on my blog is crystal clear:

“The decision is that he is neither guilty nor innocent doesn’t mean he doesn’t need to do work within his practice, and the FDA obviously needs to pursue things as well

As I said on the Saturday Google+ Hangout, I consider myself to be a Skeptic Skeptic [8]

In other words, if you are going to be a true Skeptic, at least police yourself and “fact-check” before you insert foot-in-mouth and spread misinformation, disinformation, misdirection, and / or lies all over social media

Making lame excuses for NOT debating on my blog is like an atheist stating that they would NOT debate on Earth because creationists claim it was created by God
——————————————————————
“Failure to complete and publish trials is the single biggest reputational issue Burzynski has and it cannot be waved away or covered with a fig leaf of a single rejected paper”

“If you can’t understand why this is a problem, then we’re all wasting our time even talking to you”
——————————————————————
#FaIL [9]

YOUR failure to provide any citation(s), reference(s), and / or link(s) from the Declaration of Helsinki, United States Food and Drug Administration, National Cancer Institute (NCI) at the National Institutes of Health (NIH), or any other source to support your claim as to when you think Burzynski is required to publish, says it all
——————————————————————
“The average time from commencement of a trial to completion is 3-5 years”

“If a trial is going to be completed and published, very few take longer than 8 years to final publication”
——————————————————————
3/29/1996, then United States Food and Drug Administration Commissioner, David Kessler told the American people [10]:

2. The … FDA’s initiatives … will allowthe agencyto rely on smaller trialsfewer patients … if there is evidence … of partial response in clinical trials

A. What is the FDA’s definition of “smaller trials”?

B. What is the FDA’s definition of “fewer patients”?

Burzynski’s 2006 publication lists 1652 adults and 335 children (1,799 Total) [11]

20131003-184941.jpg
“A quick sample says that the first 60 of Burzynski’s phase 2 trials were all registered on the same day”

“1 November 1999, presumably following the consent decree which forbade him from administering antineoplastons outside of a registered clinical trial”
——————————————————————
fAil [11]

If you’re correct; which is rare, 3/29/1996, why did then US FDA Commissioner, David Kessler tell the American people [10]:

6. The uhh agency hasMANY … trials … has has approved trialsfor patientswith antineoplastons ?

Why does Burzynski’s 11/25/1997 SEC Form 10-SB filing list 72 phase 2 clinical trials ? [12]

Could it be because you are wrong ?
——————————————————————
“The trial that completed, was finished in February 2005”
——————————————————————
Are you certain ? [13]

20131003-182641.jpg

20131003-182705.jpg
“The single phase 3 trial is withdrawn”
——————————————————————
Guy, did you contact the National Cancer Institute (NCI) at the National Institutes of Health (NIH) like I did, where they advised me: “Not every cancer clinical trial taking place in the United States is listed on our NCI Clinical Trials Database” ? [14]
——————————————————————
“I do not choose to debate on DJT’s blog”
——————————————————————
Guy, can you see the yellow stripe down your back ?

(I won’t say “spine,” because you haven’t shown that you have one)
——————————————————————
“He has a long history of misrepresenting differences of opinion as evidence of deceit (e.g. his claim that 0/61 is evidence that I can’t count, rather than what tit is, brevity during a rapid exchange of suggested questions during a Google hangout, where the person to whom the suggestion is made, is fully aware of the full context of 0/1/61 published/complete/registered”
——————————————————————
Guy, why don’t you just PROVE IT ?

20131003-201924.jpg

20131003-202235.jpg
#fAiL

Guy, hasn’t ONE been completed ?

20131003-202310.jpg
You wanted him to publish before the clinical trials were finished ?
——————————————————————
“So that kind of stuff is not the actions of an honest broker”
——————————————————————
Guy, what do you call all of your above FAILS?
——————————————————————
“I wouldn’t expect DJT to debate here, nor would I be interested in giving him a platform; am happy to debate in an open forum where there are comprehensible questions and some sort of moderation to prevent tactics such as the Gish gallop”
——————————————————————
Talk about “Gish galloping”

First you post: I wouldn’t expect DJT to debate here … “

and then you posted: ” … nor would I be interested in giving him a platform …”

which just shows that you were NOT sincere when you posted your 1st comment

What you are basically saying when you posted: ” … I am happy to debate in an open forum where there are comprehensible questions and some sort of moderation to prevent tactics such as the Gish gallop, is that you are NOT competent enough to call “Gish gallop” and prove it during any debate

You want “Mommy” to protect you from someone who is more intelligent than you are ?

That’s what I hear you saying
——————————————————————
“Sorry, your blog is not an “open forum” and the majority of what’s written there is gibberish”
——————————————————————
I understand you

My blog is meant for intelligent people who can grasp ideas, dry wit, and other concepts humans use to communicate with each other

Unfortunately, I take it you are NOT like the other 9,600* people who have visited my blog
——————————————————————
“I recommend you stop trying to satirise someone else’s style and instead write in your own words”
——————————————————————
Why would I take any advice from you ?

You’re one FAIL after another

I’ll satirize (and spell it correctly) that Ph.D. FAIL “Orac” all I want
——————————————————————
“And read them back, if necessary to a friend, so that you get the general air of “what the hell does that even mean?””

“knocked out of it”
——————————————————————
It’s readily apparent who needs to check them self

Because you act as if you’ve been “knocked out of it” for quite some time

Maybe you should wear a helmet
——————————————————————
“Twitter is about rapid-fire debate”
——————————————————————
What the problem is ?

“The Skeptics™” think Twitter is a “debate forum”, but you do NOT have the cranial capacity to “debate”

What “The Skeptics™” do is called “mental bastardization”
——————————————————————
“Don’t pretend that any statement is ever intended to be a nuanced and scientifically rigorous statement of the prevailing consensus view, because it isn’t, and it’s not pretending to be”
——————————————————————
As far as I’m concerned, the vast majority of your twits are “pretending”
——————————————————————
“It’s fair to ask for a source or a clarification, it’s grossly misleading to cherry-pick individual tweets and misrepresent a lack of detail as deliberate malfeasance”
——————————————————————
The FACT is, a plethora of your twittering has as its source, your posterior
——————————————————————
“That’s the kind of tactic that gets you ignored and dismissed as a mendacious time-sink; if that’s the image you’re striving for then fine but I don’t think it is”
——————————————————————
Everyone already knows what you are

Guy “Crapman”
——————————————————————
“There you go”
——————————————————————
I could NOT have said it better myself
——————————————————————
“And now, if you don’t mind, I will get on with other things”
—————————————————————
LIKE THIS ?

EXPLAIN THIS [15]

20131003-225353.jpg

20131003-232222.jpg

20131002-101725.jpg
Prove I spammed 🙂

Are you a man ?

Or are you a

SkeptiCoward© ?

20131004-013014.jpg

20131004-013041.jpg

20131004-013113.jpg

20131004-013506.jpg
======================================
REFERENCES:
======================================
[1] – 10/2013 – A Message to DJT
——————————————————————
http://t.co/Rd9CVSaKcq
——————————————————————
http://www.chapmancentral.co.uk/blahg/2013/10/a-message-to-a-djt/
======================================
[2] – 3/24/2013 – Critiquing “Burzynski: Another fact-blind troll, who predicted that?”:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/24/critiquing-burzynski-another-fact-blind-troll-who-predicted-that/
======================================
[3] – 4/12/2013 – The dishonesty of Guy Chapman, “The Skeptics” shill:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/12/the-dishonesty-of-guy-chapman-the-skeptics-shill/
======================================
[4] – 5/5/2013 – guychapman (Guy Chapman) Critiquing “The Skeptic” Burzynski Critics: A Film Producer, A Cancer Doctor, And Their Critics (page 9):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/05/05/guychapman-guy-chapman-critiquing-the-skeptic-burzynski-critics-a-film-producer-a-cancer-doctor-and-their-critics-page-9/
======================================
[5] – 4/25/2013 – Burzynski: The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-the-fdas-drug-review-process-ensuring-drugs-are-safe-and-effective/
======================================
[6] – 9/30/2013 – Bob Burzynski Skeptic Sez Multiforme Manuscript Meme Message Memorable:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/30/bob-burzynski-skeptic-sez-multiforme-manuscript-meme-message-memorable/
======================================
[7] – About | Didymus Judas Thomas’ Hipocritical Oath Blog
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/about/
======================================
[8] – 10/3/2013 – “The Skeptics™” Definition of “Debate”:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/10/03/the-skeptics-definition-of-debate/
======================================
[9] – 4/25/2013 – Burzynski: Declaration of Helsinki:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-declaration-of-helsinki/
======================================
[10] – 6/8/2013 – WHAT IS MISDIRECTION? Critiquing “Antineoplastons: Has the FDA kept its promise to the American people ?”:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/08/what-is-misdirection-critiquing-antineoplastons-has-the-fda-kept-its-promise-to-the-american-people/
======================================
[11] – Treatments for Astrocytic Tumors in Children: Current and Emerging Strategies. Pediatric Drugs 2006;8:167-178. (Pediatr Drugs 2006; 8 (3)), 2.3. Targeted Therapy, pg. 174
——————————————————————
8/21/2013 – Critiquing David H. Gorski, MD, PhD, FACS http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/21/critiquing-david-h-gorski-md-phd-facs-www-sciencebasedmedicine-orgeditorial-staffdavid-h-gorski-md-phd-managing-editor/
======================================
[12] – 7/9/2013 – Burzynski: The Original 72 Phase II Clinical Trials:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/09/burzynski-the-original-72-phase-ii-clinical-trials/
======================================
[13] – 6/26/2013 – Burzynski: The Clinical Trials:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/26/burzynski-the-clinical-trials/
——————————————————————
http://clinicaltrials.gov/archive/NCT00003509/2009_05_26/changes
======================================
[14] – 4/26/2013 – Burzynski: Not Every Cancer Clinical Trial Taking Place In The United States Is Listed On Our NCI Clinical Trials Database:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/26/burzynski-not-every-cancer-clinical-trial-taking-place-in-the-united-states-is-listed-on-our-nci-clinical-trials-database/
======================================
[15]
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/23408699/
======================================

Critiquing: Peter “Head in Ditch” Bowditch @RatBags.com

Peter “Head in Ditch” Bowditch @RatBags.com is one of the SkepTicks, The Skeptics™ SkeptiCowards©, who, like Dr. David H. “Orac” Gorski; of Wayne State University and Barbara Ann Kaplan Cancer Center / Institute in Detroit, Michigan “Fame” and Perfessor Robert J. (call me Bob) Blaskiewicz Blatherskitewicz Faux Skeptic Exposed! of University of Wisconsin, Eau Claire
“Fame” and Adam Jacobs of DianthusMed of Dianthus Medical Limited of London, United Kingdom “Fame” and @endless_psych and David James, et al., are too SkeptiCoward© to debate on-line or in person, but hide behind their keypads like a troll underneath a bridge
======================================
David James (@StortSkeptic) tweeted at 7:08pm – 1 Aug 13:

The new Doctor Who will be Stanislaw #Burzynski. He manages to continually avoid getting cornered and he gets away with murder.

——————————————————————
David Gorski (@gorskon) tweeted at 11:02pm – 1 Aug 13:

======================================
Funny how Gorski who posted this on his blog:
——————————————————————
Twitter

Gorski mentions an individual who posted tweets:
——————————————————————
“I will call you out publicly”
——————————————————————
“appears to be just a money laundry for a lying quack fraud”
——————————————————————
and:
——————————————————————
“when Laura dies #Burzynski will just move on to his next mark if she doesn’t run out of money first”
——————————————————————
BurzynskiSaves (@BurzynskiSaves) tweeted at 7:42pm – 25 Dec 11:

“@RatbagsDotCom:They will be even more vulnerable when Laura dies and #Burzynski forgets her and moves on to the next mark” #unconscionable https://twitter.com/BurzynskiSaves/status/151115741888909312
——————————————————————
Gee, willikers!

Is that YOU, Peter Bowditch (also known as HeadInDitch)?
@RatbagsDotCom

——————————————————————
But instead of calling someone out for being a twit and twitting:
——————————————————————
“Stanislaw #Burzynski. He manages to continually avoid getting cornered and he gets away with murder.”
——————————————————————
he simply twits back to them like the HACK he is
======================================
Critiquing: In which the latest movie about Stanislaw Burzynski “cancer cure” is reviewed…with Insolence:
https://stanislawrajmundburzynski.wordpress.com/2013/07/18/critiquing-in-which-the-latest-movie-about-stanislaw-burzynski-cancer-cure-is-reviewed-with-insolence-2/
======================================
You probably will NOT see that any of them have posted any comments to my blog anytime in the near future, because as has been stated before on #Forbes, The Skeptics™ want to control any debate, which is why the above type individuals block individuals like me from posting to their blogs, because they want their questions answered, but they do NOT want that type of dialogue to be the proverbial ““Two-Way Street”
======================================
Forbes Learns a Lesson, but Not the Right One: Censorship and Bias re: A Film Producer, A Cancer Doctor, And Their Critics;
https://stanislawrajmundburzynski.wordpress.com/2013/05/05/forbes-learns-a-lesson-but-not-the-right-one-censorship-and-bias-re-a-film-producer-a-cancer-doctor-and-their-critics/
======================================
For instance, they want to be able to post their Soviet-styled Dezinformatsiya without being held accountable for the veracity of the information on their blogs, Twitter, and elsewhere on Al Gore’s Internet

The difference between The Skeptics™ and I is that I actually believe in and practice “Freedom of Speech” while they block people’s comments because they do NOT have “The Right Stuff” and they can’t handle the truth, thank you, Jack Nicholson

If Dr. David H. “Orac” Gorski had to explain WHY all 33 of the patients in this phase II (2) clinical trial DIED, I am sure “Orac” is god could come up with plenty of excuses why traditional medicine did NOT save them, but if those patients had been Burzynski patients and lived, then Gorski would try to make a lot of excuses why the “standard of care” that did NOT save them, saved them if they were under Burzynski’s care
======================================
1/1/2005 (11/24/2004) – Role of temozolomide after radiotherapy for newly diagnosed diffuse BRAINSTEM GLIOMA in children:

results of a multiinstitutional study (SJHG-98)
http://www.ncbi.nlm.nih.gov/pubmed/15565574
Cancer. 2005 Jan 1;103(1):133-9.
http://www.ncbi.nlm.nih.gov/m/pubmed/15565574
Cancer 103, 133-139
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/abstract;jsessionid=6717837591CCC8FCBD8E46163808E221.d03t01
Cancer
Volume 103, Issue 1, pages 133–139, 1 January 2005
http://onlinelibrary.wiley.com/doi/10.1002/cncr.20741/full
Article first published online: 24 NOV 2004
DOI: 10.1002/cncr.20741

Department of Hematology-Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
——————————————————————
Hypocrites
======================================
Gorski defines a “CRANK” as someone who does better research than he does
——————————————————————
David Gorski (@gorskon) tweeted at 3:24am – 14 Jul 13:

@Funkmon @HoracioHornblow Ha ha. It’s the rather pathetic crank Didymus Judas Thomas. That guy couldn’t buy a clue. #Burzynski

======================================

Critiquing: In which Orac does Stanislaw Burzynski propagandist Eric Merola a favor…

“Orac” / Dr. David H. Gorski posted his lame 6/3/2013 excuse for a review of Burzynski: Cancer Is Serious Business, Part II (2), and I critiqued it:

Critiquing: In which the latest movie about Stanislaw Burzynski “cancer cure” is reviewed…with Insolence:
https://stanislawrajmundburzynski.wordpress.com/2013/07/18/critiquing-in-which-the-latest-movie-about-stanislaw-burzynski-cancer-cure-is-reviewed-with-insolence-2/
7/17/2013 Gorski pushed out his “best” effort:

In which Orac does Stanislaw Burzynski propagandist Eric Merola a favor…
http://scienceblogs.com/insolence/2013/07/17/in-which-orac-does-stanislaw-burzynski-propagandist-eric-merola-a-favor/
After my Epic Sharknado Deconstruction of “Orac’s” “review,” I thought it only fair to continue the feeding frenzy with a Burzynski Texas Tornado

Believe it or not, I’m going to do “Dr.” Gorski (who particularly likes me, to the point of thinking, apparently, that I’m a white research supremacist) a favor

“Dr.” Gorski, as you recall, is a supposed “Doctor,” oncologist, breast cancer specialist, cancer (cough-cough) “researcher” who was responsible for two dubious propaganda reviews about documentary films which Eric Merola made re: Stanislaw Burzynski, the cancer doctor who has used “antineoplastons” to treat cancer without having published any final clinical trial evidence that they do what he claims, since his 1st completed phase II (2) clinical trial in 2009

However, no worries

M. D. Anderson did a clinical trial in 2006 and did NOT publish the final results until 6-7 years later, 2/13/2013

Based on that criteria, Burzynski has until 2016-2017 to publish

Back in 2010, Merola released the first of a dynamic duo of films, the first of which was called Burzynski The Movie: Cancer Is A Serious Business (as Gorski likes to call it, by adding an “A” in the title)

The sequel, the slightly less pretentiously titled Burzynski: Cancer Is A Serious Business, Part 2 (as Gorski again likes to call it with the “A”), was then released June 1 on various pay-per-view modes

As has been pointed out, it’s better than the first, and it features direct attacks on The Skeptics™, or SkeptiCowards©, if you will, who had the temerity to criticize Burzynski and Merola over the last couple of years with their school-yard bully attacks, NOT having the intestinal testicular fortitude to back up their claims with any citation(s), reference(s), and / or link(s) in support of their blatherskite, which they found worthy enough to defend on my blog

Merola is apparently trying to recreate the success of his previous strategy, which involved letting people watch the movie online for free for limited periods of time on websites like Mercola.com

I link directly to the Mercola.com link to the second Burzynski movie, because I want to give Mercola more Google juice than he already has

The movie was, however, on Vimeo until July 20:

BURZYNSKI: CANCER IS SERIOUS BUSINESS, PART II (2013) from BurzynskiMovie on Vimeo
http://articles.mercola.com/sites/articles/archive/2013/07/13/burzynski-cancer-film.aspx
If you want to see what the fuss was about and whether my criticisms of The Skeptics™, or SkeptiCowards©, were valid, now’s your chance

If you want to see the highlighted attack on The Skeptics™ SkeptiCowards©, it begins around 1:19 h into the movie

Yes, I’m encouraging you to watch Burzynski 2

It’s a beautiful example of all the things that Gorski tried to inculcate #TAM2013 attendees against

Indeed, dissecting this magnum opus is an excellent way to teach oneself critical thinking, much as dissecting creationist tripe is

Unfortunately, Gorski is unable to do this, because individuals like me, exist and will NOT let him get away with his disingenuous hack attacks

Other key points include:

Laura Hymas interview and the recording of her discussion with her oncologist (approximately 0:28 h in)

This section is horrifying (to Gorski, at least) to watch, as he can’t help but feel how dicey and ethical the situation that poor UK NHS oncologist found himself in with Hymas and her family demanding that he help her be part of one of Burzynski’s “clinical trials” by agreeing to be the local physician and agreeing to order various scans

The end of the story of Amelia Saunders (approximately 0:58 h in)

This is one where Merola caused Gorski true revulsion, as he basically implied that Amelia died because her parents took her off the antineoplastons

Or you can read what Eric Merola REALLY posted on Twitter:
https://stanislawrajmundburzynski.wordpress.com/2013/04/18/fact-checking-httpthehoustoncancerquack-com/
Hideaki Tsuda’s clinical trial (approximately 1:31 h in)

Gorski wonders why he hasn’t yet published, just like he wonders why Burzynski hasn’t published, but Gorski, SkeptiCoward© that he is, can NOT seem to explain why The Lancet Oncology Peer Review Team D-12-01519 refused to publish Burzynski’s 11/26/2012 (1:29:53) phase 2 clinical trial Progression-Free Survival (PFS) and Overall Survival (OS) re patients 8 – 16 years after diagnosis, results

Those of you who watch it, let Gorski know what you think

Those of you who can only watch part of it, let Gorski know what you think of that section

Remember, though, Gorski will BLOCK you if you question HIS infallibility, because he and his “Oracolytes” would rather comment on things that have NOTHING WHATSOEVER to do with Burzynski, like:

“it is possible to link without boosting google rankings through the “no-follow command”: http://en.wikipedia.org/wiki/Nofollow I learned about this from Bob Blaskiewicz, who proposed that we use this when linking to dubious websites in our posts”

Gorski makes unreliable excuses for NOT doing research re Burzynski, so I did it for him

Burzynski: Complete Response, Partial Response, Stable Disease, Progressive Disease, Objective Response, and Response:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-complete-response-partial-response-stable-disease-progressive-disease-objective-response-and-response/
Burzynski: Progression-Free Survival (PFS):
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-progression-free-survival/
Antineoplastons: Adverse Effects:
https://stanislawrajmundburzynski.wordpress.com/2013/07/02/antineoplastons-adverse-effects/
Burzynski: Acknowledgements, Authors, and Co-Investigators:
https://stanislawrajmundburzynski.wordpress.com/2013/07/03/burzynski-acknowledgements/
Burzynski: Institutional Review Board (IRB):
https://stanislawrajmundburzynski.wordpress.com/2013/07/02/burzynski-institutional-review-board-irb/
And because Gorski and others do NOT seem to understand how antineoplastons (ANP) A10 (Atengenal) and AS2-1 (Astugenal) work, I provide the relevant Burzynski publications and page #’s for them to review:
http://www.burzynskiclinic.com/scientific-publications.html
======================================
Interim Reports on Clinial Trials
16. 2003 (BT-11)
Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.
DRUGS IN R&D
http://www.ncbi.nlm.nih.gov/pubmed/12718563
Drugs in R and D
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
(Drugs in Research and Development)
http://www.burzynskiclinic.com/images/stories/Publications/960.pdf
Drugs R D. 2003;4(2):91-101
Drugs in R&D 2003;4:91-101

Pg. 92
Antineoplaston A10 and AS2-1 are synthetic derivatives of phenylacetate (PN) acid, glutamine and isoglutamine

A10 is sterile solution of sodium phenylacetylisoglutiminate (isoPG) in 4 : 1 ratio

Antineoplaston AS2-1 is sterile solution of sodium phenylacetate (PN) and phenylacetylglutaminate (PG) in 4 : 1 ratio

Pg. 97
Discussion
Pg. 99

======================================
Review Articles on Clinical Trials:
1. 3/2004
The Present State of Antineoplaston Research
http://www.burzynskiclinic.com/images/stories/Publications/994.pdf
Integrative Cancer Therapies 2004;3:47-58
Volume 3, No. 1, March 2004
DOI: 10.1177/1534735-403261964
Volume 3 Number 1 March 2004

Pg. 47
Pg. 48
Mechanism of Action of Antineoplaston
Pg. 49
Pg. 50

The reason for 50% Progressive Disease (PD) in studies is long dose-escalation process, which extends to more than a month’s time period, before the optimal dosage is reached

Pg. 56
Conclusion

======================================
Case Reports:
4. 9/2004 (Special Exception (SE) to BT-11 Study (ST))
Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme
http://www.burzynskiclinic.com/images/stories/Publications/1145.pdf
Integrative Cancer Therapies 2004;3:257-261
Volume 3, Number 3 September 2004
DOI: 10.1177/1534735404267748

Pgs. 257-258
Pg. 260
Discussion
Pg. 261

======================================
Interim Reports on Clinial Trials:
2. 10/2004
Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme
http://www.burzynskiclinic.com/images/stories/Publications/1218.pdf
Neuro-Oncology. 2004; 6: 384
Volume 6 Issue 4 October 2004
Abstracts from the Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004

Pg. 385
======================================
Interim Reports on Clinial Trials:
3. 10/2004 (Study (ST) and Special Exception (SE))
Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma
http://www.burzynskiclinic.com/images/stories/Publications/1219.pdf
Neuro-Oncology. 2004; 6: 386
Volume 6 Issue 4 October 2004

Antineoplastons (ANP) consist of 3 active ingredients including sodium salts of phenylacetylglutamine (PG), phenylacetylisoglutimine (isoPG), and phenylacetic acid (PN)

Preclinical data supports that the mechanism of antineoplastic activity in DBSG, involves interruption of signal transmission in the RAS, (PN) AKT2, and TGFB1 (PG) pathways, activation of p53 and p21 tumor suppressor genes (PN) and apoptosis (PG and isoPG)

======================================
Interim Reports on Clinial Trials:
17. 2004 (BT-13 and BT-23)
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma :
a preliminary report
DRUGS IN R&D
http://www.ncbi.nlm.nih.gov/pubmed/15563234
Drugs in R and D
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
(Drugs in Research and Development)
http://www.burzynskiclinic.com/images/stories/Publications/1194.pdf
Drugs R D. 2004;5(6):315-26
Drugs R&D 2004;5(6):315-326.

Pg. 316
Pg. 324
Discussion

======================================
Interim Reports on Clinial Trials:
18. 6/2005 (CAN-01 and BT-12)
Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V.
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 and AS2-1
http://www.ncbi.nlm.nih.gov/pubmed/15911929
Integr Cancer Ther. 2005 Jun;4(2):168-77
http://www.ncbi.nlm.nih.gov/m/pubmed/15911929
Integrative Cancer Therapies 2005;4(2):168-177
http://www.burzynskiclinic.com/images/stories/Publications/1220.pdf
DOI: 10.1177/1534735405276835
http://m.ict.sagepub.com/content/4/2/168.long?view=long&pmid=15911929
Volume 4 Number 2 June 2005

Pg. 168
Pg. 174
Discussion
Pgs. 175-176

======================================
Interim Reports on Clinial Trials:
19. 3/2006 (BT-03, BT-11, BT-18, and CAN-01)
Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive brainstem glioma.
http://www.ncbi.nlm.nih.gov/pubmed/16484713
Integr Cancer Ther. 2006 Mar;5(1):40-7
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
Integrative Cancer Therapies 2006;5(1):40-47
http://www.burzynskiclinic.com/images/stories/Publications/5825.pdf
DOI: 10.1177/1534735405285380
http://m.ict.sagepub.com/content/5/1/40.long?view=long&pmid=16484713

Pgs. 40-41
Pg. 46
Discussion
Conclusion

======================================
Interim Reports on Clinial Trials:
8. 10/2006
Treatment of multicentric brainstem gliomas with antineoplastons (ANP) A10 and AS2-1.
http://www.burzynskiclinic.com/images/stories/Publications/2105.pdf
Neuro-Oncology. 2006; 8:466.
Volume 8 Issue 4 October 2006
Abstracts for the Eleventh Annual Meeting of the Society for Neuro-Oncology (SNO)

Pg. 466
Antineoplastons (ANP) are synthetic analogues of naturally occurring phenylacetylglutamine (PG), phenylacetylisoglutimine (isoPG), and phenylacetate (PN)

======================================
Review Articles on Clinical Trials:
3. 12/2007
Recent clinical trials in diffuse intrinsic brainstem glioma. Cancer Therapy 2007; 5, 379-390.
http://www.burzynskiclinic.com/images/stories/Publications/5692.pdf
Review Article
Cancer Therapy Vol 5, 379-390, 2007
http://www.cancer-therapy.org/CT/v5/B/HTML/42._Burzynski,_379-390.html
Volume 5 Number 2 December, 2007

Pg. 381
Pg. 384
E. Multitargeted therapy

======================================
Interim Reports on Clinical Trials:
11. 10/2008
(BT-8 – PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
(BT-15 – ADULT PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma:
A preliminary report
http://www.burzynskiclinic.com/images/stories/Publications/7853.pdf
Volume 10 Issue 5 October 2008
Neuro-Oncology 2008; 10:821
Abstracts for the Thirteenth Annual Meeting of the Society for Neuro-Oncology, November 20-23, 2008

Pg. 821

Antineoplastons (ANP) are synthetic analogs of naturally occurring phenylacetylglutamine (PG), phenylacetylisoglutimine (isoPG), and phenylacetate (PN)

Antineoplastons (ANP) is a multi-targeted therapy affecting signal transduction, the cell cycle, the TCA cycle, and apoptosis

======================================
Interim Reports on Clinical Trials:
12. 12/2008
(BT-8 – PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
(BT-15 – ADULT PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma
http://www.burzynskiclinic.com/images/stories/Publications/7898.pdf
Neuro-Oncology 2008; 10:1067
Volume 10 Issue 6 December 2008
Abstracts for the Eighth Congress of the European Association for Neuro-Oncology (EANO), Sept. 12-14, 2008, Barcelona, Spain

Antineoplastons (ANP) affects multiple targets, and its components have different mechanisms of action

A10 interferes with signaling in the AKT2 and MYCC pathways, blocks expression of TGFB1, activates the PTEN and MAD tumor suppressor genes, and normalizes nuclear transport by decreasing the expression of RANBP1, which may restore the activity of the mutated INI protein

AS2-1 interferes with signal transmission in the RAS and BCL2 pathways and activates expression of the tumor suppressors TP53 and p21

======================================
Case Reports:
1. 12/2009 (BT-11 Special Exception (SE))
Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP).
http://www.burzynskiclinic.com/images/stories/Publications/8638.pdf
Neuro-Oncology 2009; 11:923.
Volume 11 Issue 6 December 2009
Abstracts from the Third Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) and the Sixth Meeting of the Asian Society for Neuro-Oncology (ASNO), May 11-14, 2009, Yokohama, Japan

Antineoplastons (ANP) is a multi-targeted therapy that is well tolerated with minimal and reversible adverse events and has multiple different mechanisms of action by affecting the AKT, RAS, TP53, p21, and PTEN pathways
======================================

WHAT IS MISDIRECTION? Critiquing “Antineoplastons: Has the FDA kept its promise to the American people ?”

March 29, 1996

Then United States Food and Drug Administration Commissioner, David Kessler told the American people:

1. We will eliminate unnecessary paperwork … that used to delay or discourage … cancer research … by non-commercial clinical investigators

2. The … FDA’s initiatives … will allow …the agency … to rely on smaller trialsfewer patients … if there is evidence … of partial response in clinical trials

I don’t want to get into any particular … agent … except let me point out … that … the information needs to be part … of clinical trials

3. We will accept … less informationup front

4. we’re going to require further study AFTERapproval … because the science … has matured

5. The important – point … is that information needs to be gathered … through scientific means … through clinical – trials … and I think – that’s … that’s very important uhh very … important point

You can’t … just … use an agent here – or there … you have to use it … as part of a clinical trial … so we can get information … on whether the drug works

6. The uhh agency has … many … trials … has has approved trials … for patients … with antineoplastons

7. We are committed to providing expanded access … availability … for American patients for any drug … there’s reason to believe … may work
——————————————————————
BOTTOM LINE:
——————————————————————
Everything else is MISDIRECTION
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/03/22/antineoplastons-has-the-fda-kept-its-promise-to-the-american-people
——————————————————————
A. What is the FDA’s definition of “unnecessary paperwork”?

B. What is the FDA’s definition of “smaller trials”?

C. What is the FDA’s definition of “fewer patients”?

D. What is the FDA’s definition of “evidence … of partial response“?

E. What is the FDA’s definition of “less information … up front”?

F. What is the FDA’s definition of “we’re going to require further study AFTER … approval”?

G. What is the FDA’s definition of “We are committed to providing expanded access … availability … for American patients for any drug … there’s reason to believe … may work”?
======================================
2003 – 2009 Phase II preliminary
——————————————————————
2003 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
Drugs R D. 2003;4(2):91-101
(Drugs in R and D / Drugs in Research and Development)

2003: Protocol – recurrent diffuse intrinsic brain stem glioma

12 – Patients Accrued
10 – Evaluable Patients

2 / 20% – # and % of Patients Showing Complete Response
3 / 30% – # and % of Patients Showing Partial Response
3 / 30% – # and % of Patients Showing Stable Disease
2 / 20% – # and % of Patients Showing Progressive Disease
======================================
http://www.burzynskiclinic.com/scientific-publications.html
Interim Reports on Clinial Trials:

1. 10/2003

NEURO-ONCOLOGY

Burzynski, S.R., Weaver, R.A., Bestak, M., Lewy, R.I., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I.

Phase II study of Antineoplastons A10 and AS2-1 (ANP) in children with recurrent and progressive MULTICENTRIC GLIOMA

A preliminary report
http://www.burzynskiclinic.com/images/stories/Publications/970.pdf
Neuro-Oncology. 2003; 5: 358
Volume 5 Issue 4 October 2003

10/2003 – Protocol – MULTICENTRIC GLIOMA

12 – Children Patients Accrued
10 – Evaluable Patients
(9 months-17 years / 9 – median age)

4 / 33% – # and % of Patients Showing Complete Response
2 / 25% – # and % of Patients Showing Partial Response
4 / 33% – # and % of Patients Showing Stable Disease
0 / 0% – # and % of Patients Showing Progressive Disease
1 / 9% – # and % of Patients Nonevaluable due to only 4 weeks of treatment / lack of follow-up scans
======================================
Interim Reports on Clinial Trials:

16. 2003

DRUGS IN R&D
Drugs in R and D
(Drugs in Research and Development)

BT-11
BRAIN STEM GLIOMA

Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA:

a preliminary report.
http://www.ncbi.nlm.nih.gov/pubmed/12718563
Burzynski, S.R., Lewy, R.I., Weaver, R.A., Axler, M.L., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I., Bestak, M.
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
Drugs R D. 2003;4(2):91-101
Drugs in R&D 2003;4:91-101
http://www.burzynskiclinic.com/images/stories/Publications/960.pdf

Pgs. 91-92 and 95

3/1996 – Protocol – recurrent diffuse intrinsic BRAIN STEM GLIOMA (3/1996 – 5/1999 enrolled / Pg. 94)

12 – Patients Accrued (6 males / 6 females)
(4-29 years / 10 – median age)
10 – Evaluable Patients

2 / 20% – # and % of Patients Showing Complete Response
3 / 30% – # and % of Patients Showing Partial Response
3 / 30% – # and % of Patients Showing Stable Disease
2 / 20% – # and % of Patients Showing Progressive Disease
======================================
2004 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
Drugs R D. 2004;5(6):315-26
(Drugs in R and D / Drugs in Research and Development)

2004: Protocol – incurable recurrent and progressive multicentric glioma

12 – Patients Accrued
(9 – median age)
11 – Evaluable Patients

4 / 33% – # and % of Patients Showing Complete Response
3 / 25% – # and % of Patients Showing Partial Response
4 / 33% – # and % of Patients Showing Stable Disease
0 / 0% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

2. 10/2004

NEURO-ONCOLOGY

BT-20
Patients With GLIOBLASTOMA MULTIFORME (GBM)

Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgopolov, V.

Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent GLIOBLASTOMA MULTIFORME
http://www.burzynskiclinic.com/images/stories/Publications/1218.pdf
Neuro-Oncology. 2004; 6: 384
Volume 6 Issue 4 October 2004
Abstracts from the Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004

Pg. 385

10/2004 – Protocol – glioblastoma multiforme (GBM) which recurred or progressed post surgery, radiation therapy, and / or chemotherapy

22 – Evaluable Patients
(6 men / 16 women / 27-63 /47 – median age)

1 / 4.5% – # and % of Patients Showing Complete Response
1 / 4.5% – # and % of Patients Showing Partial Response
12 / 54.5% – # and % of Patients Showing Stable Disease
8 / 36.5% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

3. 10/2004 (DBSG)

NEURO-ONCOLOGY

Burzynski, S.R., Weaver, R. Bestak. M., Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.

Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic BRAIN STEM GLIOMA
http://www.burzynskiclinic.com/images/stories/Publications/1219.pdf
Neuro-Oncology. 2004; 6: 386
Volume 6 Issue 4 October 2004

60 patients
(31 didn’t meet admission criteria to the study and were treated under Special Exception (SE))

10/2004 – Protocol – patients with diffuse intrinsic BRAIN STEM GLIOMA (DBSG)

29 – Evaluable Patients

7 / 24% – # and % of Patients Showing Complete Response
6 / 21% – # and % of Patients Showing Partial Response
6 / 21% – # and % of Patients Showing Stable Disease
10 / 34% – # and % of Patients Showing Progressive Disease
——————————————————————
31 – Evaluable Patients: Special exception (SE)

5 / 16% – # and % of Patients Showing Complete Response
2 / 6% – # and % of Patients Showing Partial Response
16 / 52% – # and % of Patients Showing Stable Disease
8 / 26% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

4. 10/2004 (AT/RT of CNS)

NEURO-ONCOLOGY

BT-14

CHILDREN WITH RHABDOID TUMOR OF THE CENTRAL NERVOUS SYSTEM

Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.

Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system

A preliminary report
http://www.burzynskiclinic.com/images/stories/Publications/1146.pdf
Neuro-Oncology. 2004; 6: 427
Volume 6 Issue 4 October 2004
Abstracts from the Eleventh International Symposium on Pediatric Neuro-Oncology, Boston, Massachusetts, June 13-16, 2004

10/2004 – Protocol – children with atypical teratoid / rhabdoid tumors (AT / RT) of the central nervous system

11 – Children Patients Accrued
8 – Evaluable Patients
(7 treated under Special Exception (SE))

2 / 25% – # and % of Patients Showing Complete Response
1 / 12.5% – # and % of Patients Showing Partial Response
1 / 12.5% – # and % of Patients Showing Stable Disease
4 / 50% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

5. 10/2004

NEURO-ONCOLOGY

BT-12

CHILDREN WITH PRIMITIVE NEUROECTODERMAL TUMORS (PNET)

Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V.

Treatment of PRIMITIVE NEUROECTODERMAL TUMORS (PNET) with antineoplastons A10 and AS2-1 (ANP)

Preliminary results of phase II studies
http://www.burzynskiclinic.com/images/stories/Publications/1147.pdf
Neuro-Oncology. 2004; 6: 428
Volume 6 Issue 4 October 2004
Abstracts from the Eleventh International Symposium on Pediatric Neuro-Oncology

10/2004 – Protocol – PRIMITIVE NEUROECTODERMAL TUMORS (PNET)

17 – Patients Accrued
15 – Evaluable Patients
(12 months – 23 years / 6 – median age)

3 / 20% – # and % of Patients Showing Complete Response
2 / 13.4% – # and % of Patients Showing Partial Response
5 / 33.3% – # and % of Patients Showing Stable Disease
5 / 33.3% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

17. 2004

DRUGS IN R&D
Drugs in R and D
(Drugs in Research and Development)

Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Bestak, M.

Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma.

A Preliminary Report.
http://www.ncbi.nlm.nih.gov/pubmed/15563234
Drugs R&D 2004;5(6):315-326.
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
Drugs R D. 2004;5(6):315-26
http://www.burzynskiclinic.com/images/stories/Publications/1194.pdf

incurable recurrent and progressive multicentric glioma

Pg. 320

3 – treated under Special Exception (SE) granted by the US FDA

Pgs. 317 and 320

7/31/1996 – (7/31/1996 – 4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive multicentric glioma (MCG)

Pg. 317

BT-13

children with low-grade astrocytoma

BT-23

children with visual pathway gliomas


Pgs. 317 and 320-321

12 – Children Patients Accrued (Pgs. 315-316)
(9 months – 17 years / 9- median age)
(6 – male / 6 – females)
10 – Evaluable Patients (Pg. 315)

4 / 33% – # and % of Patients Showing Complete Response
3 / 25% – # and % of Patients Showing Partial Response
4 / 33% – # and % of Patients Showing Stable Disease
0 / 0% – # and % of Patients Showing Progressive Disease
1 / 9% – # and % of Patients Non-evaluable
——————————————————————
Pg. 325

Compare: Chamberlain and Grafe. [38]

1995 – Protocol – solitary recurrent chiasmatic hypothalamic gliomas treated with oral etoposide


14 – Patients Accrued
14 – Evaluable Patients

1 / 7% – # and % of Patients Showing Complete Response
4 / 29% – # and % of Patients Showing Partial Response
3 / 21% – # and % of Patients Showing Stable Disease
6 / 43% – # and % of Patients Showing Progressive Disease

Pg. 326

38. Chamberlain MC, Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995; 13: 2072-6
http://www.ncbi.nlm.nih.gov/pubmed/7636550/
J Clin Oncol. 1995 Aug;13(8):2072-6.
http://www.ncbi.nlm.nih.gov/m/pubmed/7636550/
Department of Neurosciences, University of California, San Diego, La Jolla, USA.
http://m.jco.ascopubs.org/content/13/8/2072.long
Arch Neurol. 1995 May;52(5):509-13.
http://www.ncbi.nlm.nih.gov/pubmed/7733847/
Department of Neurosciences, University of California-San Diego, USA.
http://www.ncbi.nlm.nih.gov/m/pubmed/7733847/
Arch Neurol. 1995;52(5):509-513. doi:10.1001/archneur.1995.00540290099024.
http://archneur.jamanetwork.com/Mobile/article.aspx?articleid=593460
——————————————————————
Compare: The Pediatric Oncology Group. [39]

10/2000 – Protocol – solitary progressive optic pathway tumors with carboplatin

50 – Patients Accrued
50 – Evaluable Patients

2 / 4% – # and % of Patients Showing Partial Response
37 / 74% – # and % of Patients Showing Stable Disease
11 / 22% – # and % of Patients Showing Progressive Disease

39. Mahoney DH, Cohen ME, Friedman HS, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro-oncol 2000; 2: 213-20
http://www.ncbi.nlm.nih.gov/pubmed/11265230/
Neuro Oncol. 2000 Oct;2(4):213-20.
http://www.ncbi.nlm.nih.gov/m/pubmed/11265230/
Baylor College of Medicine, Houston, TX, USA.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920597/

http://neuro-oncology.oxfordjournals.org/content/2/4/213.full.pdf
======================================
2005 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/15911929
Integr Cancer Ther. 2005 Jun;4(2):168-77
(Integrative Cancer Therapies)

2005: Protocol – recurrent disease or high risk

13 – Patients Accrued
(1-11 – age / 5 years 11 months – median age)
13 – Evaluable Patients

3 / 23% – # and % of Patients Showing Complete Response
1 / 8% – # and % of Patients Showing Partial Response
4 / 31% – # and % of Patients Showing Stable Disease
5 / 38% – # and % of Patients Showing Progressive Disease
——————————————————————
(Updated 2007)
http://www.cancer-therapy.org/CT/v5/B/HTML/42._Burzynski,_379-390.html
2005 – Protocol – incurable recurrent and progressive multicentric glioma

13 – Patients Accrued

3 / 23% – # and % of Patients Showing Complete Response
1 / 8% – # and % of Patients Showing Partial Response
4 / 31% – # and % of Patients Showing Stable Disease
5 / 38% – # and % of Patients Showing Progressive Disease
======================================
2006 – Phase II
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
Integr Cancer Ther. 2006 Mar;5(1):40-7
(Integrative Cancer Therapies)

2006: Protocol – high-grade pathology (HBSG)

– Patients Accrued
18 – Evaluable Patients

2 / 11% – # and % of Patients Showing Complete Response
2 / 11% – # and % of Patients Showing Partial Response
7 / 39% – # and % of Patients Showing Stable Disease
7 / 39% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

BT-03


BT-11

BRAIN STEM GLIOMA (BSG)

BT-18

6. MIXED GLIOMA

ADULT PATIENTS WITH MIXED GLIOMA

“mixed glioma”, a type of primary malignant brain tumor (PMBT)

BT-22

8. CHILDREN WITH PRIMARY MALIGNANT BRAIN TUMORS

CAN-01 (CAN-1)

PATIENTS WITH REFRACTORY MALIGNANCIES

19. 3/2006

Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive BRAINSTEM GLIOMA. Integrative Cancer Therapies 2006;5(1):40-47
http://www.ncbi.nlm.nih.gov/pubmed/16484713
Integr Cancer Ther. 2006 Mar;5(1):40-7
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
DOI: 10.1177/1534735405285380
http://www.burzynskiclinic.com/images/stories/Publications/5825.pdf

http://m.ict.sagepub.com/content/5/1/40.long?view=long&pmid=16484713
Pgs. 40-41

4 phase 2 trials

BRAINSTEM GLIOMA (BSG)

patients with inoperable tumor of high-grade pathology (HBSG)
glioblastoma

recurrent diffuse intrinsic glioblastomas and ANAPLASTIC ASTROCYTOMAs of brainstem

Pg. 43

BT-03 – 1 / female
BT-11 – 13 (8 males/5 females)
BT-18 – 1 / female
BT-22 – 2 / females
CAN-01 – 1 / female

Pg. 44

High-grade, recurrent, and progressive brainstem gliomas

Pgs. 40-42 and 44-45

7/12/1988 (7/12/1988 – 11/13/2003 as of 6/10/2005) – Protocol – recurrent diffuse intrinsic glioblastomas and anaplastic astrocytomas of the brainstem high-grade pathology (HBSG)

18 – Evaluable Patients (Pgs. 40-43)
(8 males / 10 females / 2-42 / 10 – median age / Pgs. 42-43)

2 / 11% – # and % of Patients Showing Complete Response
2 / 11% – # and % of Patients Showing Partial Response
7 / 39% – # and % of Patients Showing Stable Disease
7 / 39% – # and % of Patients Showing Progressive Disease
======================================
Interim Reports on Clinial Trials:

BT-11

BRAIN STEM GLIOMA

8. 10/2006

Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Khan, M.I., Dolgopolov, V. Treatment of multicentric BRAINSTEM GLIOMAs with antineoplastons (ANP) A10 and AS2-1. Neuro-Oncology. 2006; 8:466.
http://www.burzynskiclinic.com/images/stories/Publications/2105.pdf
Volume 8 Issue 4 October 2006
Abstracts for the Eleventh Annual Meeting of the Society for Neuro-Oncology (SNO)

Brainstem gliomas and multicentric tumors (MBSG)

10/2006 – Protocol – Brainstem gliomas and multicentric tumors (MBSG)

19 – Evaluable Patients
3.9 – 40.8 years (9.2 – median age)
(90% less than 18 years old)

2 / 11% – # and % of Patients Showing Complete Response
1 / 5% – # and % of Patients Showing Partial Response
7 / 37% – # and % of Patients Showing Stable Disease
9 / 47% – # and % of Patients Showing Progressive Disease
======================================
2007
http://www.burzynskiclinic.com/images/stories/Publications/1252.pdf
2004 – Protocol – small group of patients with progressive LGA, ANP
60% – % of Patients Showing Complete Response
10% – % of Patients Showing Partial Response
——————————————————————
2004 – Protocol – low-grade astrocytoma in children
Burzynski [39] – Reference
Phase II d – d = Preliminary results – Study type
P – P = progressive tumor – Tumor type
(no. of pts) – pts = patients
ANP (10) – ANP = antineoplastons A10 and AS2-1 – Treatment
10 – Evaluable Patients {(78) = most in a study}
OS [%] – OS = overall survival
100% (1 yr) – 90% (3 yr) – Efficacy
93 mo – MST = MST = median survival time – {96 (1 y) next closest}
60% (6) – % and # of Patients Showing Complete Response {24 (11) next closest}
10% (1) – % and # of Patients Showing Partial Response {60% (9) best other study}
30% (3) – % and # of Patients Showing Stable Disease + MR = minor response {70% (14) best other study}
0% (0) – % and # of Patients Showing Progressive Disease {4% (2) next closest}
PFS (%)
90 (1 y) – 90 (3 y) – PFS = progression-free survival {100 (1 y) – 68 (3 y) best other study
——————————————————————
2004 – Protocol – diffuse, intrinsic brainstem glioma in children
Burzynski et al. [88] – Reference
Phase II – Study Type
(no. of pts) – pts = patients
RP (30) – RP = recurrent and progressive tumor – Tumor type
30 – Evaluable Patients
ANP – ANP = antineoplastons A10 and AS2-1 – Treatment – ANP
OS (%) – OS = overall survival
[2y; 5y]
46.7; 30 – Efficacy
MST (mo)
19.9 – MST = median survival time
27% (8) – % and # of Patients Showing Complete Response
20% (6) – % and # of Patients Showing Partial Response
23% (7) – % and # of Patients Showing Stable Disease
30% (9) – % and # of Patients Showing Progressive Disease
——————————————————————
Burzynski et al. [89] – Reference
Phase II – Study Type
(no. of pts) – pts = patients
RPS (10) – RPS = recurrent and progressive tumors in children aged <4y – Tumor type {(66) = most in a study}
ANP – ANP = antineoplastons A10 and AS2-1 – Treatment – ANP
OS (%) – OS = overall survival
[2y; 5y] – Efficacy
60; 20 {46.7 (30) = next best study}
MST (mo)
26.3 – MST = median survival time – {19.9 = next best study}
[% (no. )]
30% (3) – CR = complete response – {27% (8) = next best study}
[% (no. )]
0% (0) – PR = partial response – {56% (1) = next best}
[% (no. )]
40% (4) – SD = stable disease – {44% (25) = best}
[% (no. )]
30% (3) – PD = progressive disease – {23% (13) = best}
� � � � � � � � � � � � � � � � �
Interim Reports on Clinial Trials:

BT-11

BRAIN STEM GLIOMA

9. 4/2007 (NDBSG)

Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplastons A10 and AS 2-1 (ANP) in children with newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs. Neuro-Oncology 2007; 9:206.
http://www.burzynskiclinic.com/images/stories/Publications/4021.pdf
Volume 9 Issue 2 April 2007
Abstracts from the Twelfth International Symposium on Pediatric Neuro-Oncology

4/2007 – Protocol – newly diagnosed diffuse, intrinsic BRAINSTEM GLIOMAs (NDBSG)

20 – Evaluable assessable children Patients
(3 months-20 years – age)

6 / 30% – # and % of Patients Showing Complete Response
2 / 10% – # and % of Patients Showing Partial Response
4 / 20% – # and % of Patients Showing Stable Disease
8 / 40% – # and % of Patients Showing Progressive Disease
� � � � � � � � � � � � � � � � �
Interim Reports on Clinial Trials:

BT-11

BRAIN STEM GLIOMA

Special exception (SE)

13. 12/2009 (DBSG)

Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S. Phase II study of antineoplastons A10 and AS2-1 in patients with BRAINSTEM GLIOMA. Protocol BC-BT-11. Neuro-Oncology 2009, 11:951.
http://www.burzynskiclinic.com/images/stories/Publications/8639.pdf
Volume 11 Issue 6 December 2009
Abstracts from the Third Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) and the Sixth Meeting of the Asian Society for Neuro-Oncology (ASNO)
May 11-14, 2009
Yokohama, Japan

12/2009 – Protocol – BRAINSTEM GLIOMAs

40 – Patients Accrued
28 – Evaluable Patients
(23 children / 5 young adults)

5 / 18% – # and % of Patients Showing Complete Response
4 / 14% – # and % of Patients Showing Partial Response
12 / 43% – # and % of Patients Showing Stable Disease
7 / 25% – # and % of Patients Showing Progressive Disease
——————————————————————
Special exception (SE)

12/2009 – Protocol – BRAINSTEM GLIOMAs

52 – Evaluable Patients
(40 children / 12 young adults)

5 / 10% – # and % of Patients Showing Complete Response
2 / 4% – # and % of Patients Showing Partial Response
28 / 54% – # and % of Patients Showing Stable Disease
17 / 32% – # and % of Patients Showing Progressive Disease
——————————————————————
BT-11 and special exception (SE)
92% – diffuse intrinsic brainstem gliomas (DBSG)

Overall survival (OS) – 2 years:
42% – special exception (SE)
36% – BT-11

Overall survival (OS) – 5 years:
19% – special exception (SE)
25% – BT-11
======================================
Compare: standard radiation therapy in combination with chemotherapy (RAT) (Mandell et al. 1999)

2% – % of Patients Showing Complete Response
31% – % of Patients Showing Partial Response

Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brain stem tumors: results of pediatric oncology group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43:959-964.
http://www.ncbi.nlm.nih.gov/pubmed/10192340/
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64.
http://www.ncbi.nlm.nih.gov/m/pubmed/10192340/
International Journal of Radiation Oncology*Biology*Physics
Volume 43, Issue 5, 15 March 1999, Pages 959–964
http://www.sciencedirect.com/science/article/pii/S036030169800501X
Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY, USA.
6/1992 – 10/1997

Overall survival (OS):
7% – 2 years
0% – 5 years
=====================================
COMBINED:
——————————————————————
Overall survival (OS) – 2 years:
——————————————————————
42% – antineoplastons: special exception (SE)

36% – antineoplastons: BT-11

7% – standard radiation therapy in combination with chemotherapy (RAT)
——————————————————————
Overall survival (OS) – 5 years:
——————————————————————
25% – antineoplastons: BT-11

19% – antineoplastons: special exception (SE)

0% – standard radiation therapy in combination with chemotherapy (RAT)
� � � � � � � � � � � � � � � � �
Break The Walls Down:

——————————————————————
And “THAT’s The BOTTOM LINE”
Because Stone Cold Said So

——————————————————————
IT’s GO TIME
Time To Play The Game:

——————————————————————
Break The Walls Down:

=====================================

The #Burzynski (B.S.) Bump Rap

Yo …

Let me tell you how it’s DONE

We don’t get paid to do IT

We just do it for FUN

We fact-check your SH*T

Until the morning SUN

We know we have you on the RUN

‘Cause you hide behind your keypad SON

We know your “C”-RAP

Because it came out from between your BUNS

And we “Smell What You’re COOKIN’”

And out it COMES

The same ol’ cr*p that rolls right off the tip of your TONGUE

Do you really believe your own HYPERBULL?

Or are you really that DUMB?

I KNOW, who I AM

I AM, Number ONE

I KNOW, who I AM

I don’t fit into your “Master Plan”

(Piss-Off)

I KNOW, who I AM

I AM Number ONE

I KNOW, who I AM

I AM, Number ONE

wiki-wiki-wiki

That’s right WIKIPEDIA

You’re NOT Number ONE

(I got HIS Number)

You threw your MUD

Then hid behind a Black-Hole SUN

You dished out your MUD-BATH

Did you think you had WON?

A Yellow-Journalism AWARD?

(THAT’s just Piss-Poor)

WikipedBiaS!

Did you say WikipediAin’t your SON?

Holy “C”-RAP!!

Did You See THAT!!!

All dressed up wearing your best CummerBUND

Did you think you could get away with thumbin’ your Nose at your own THUMB?

Dum, Dum Dum DUMB

Well here I COME

Like a little TRICKER-TREATER

Get outta here with your SCHTICK!!!

Oh NO, Here comes PETER

Yo, What’s THAT in his HAND?

I don’t think it’s a water METER

Maybe he caught another BOTTOM FEEDER!!!

Yo Yo Ma, I heard it was just another TWITTER TWEETER

Yo, Yo, Yo, YOU want “NEW” INSOLENCE?

I don’t need your “Cult” of “MUD”

“M”isinformation

“U”ndereducated

“D”isinformation

MIS-DIS-INFORMATION

Doctor DISSIMULATION

You’re the Metastasis of Misinformation

The scourge of a NATION

I heard you liked “HUSTLER”

Which explains your problem with Mental Master-Debation

Mel Brooks just called and said “HELLO BALLS”

But I heard your head was on VACATION

“You can’t handle the TRUTH”

If we got you on #MizTV

It’d be like: “really?, Really??, REALLY???”

YO

“You Can’t “C” Me”

You couldn’t handle an Epic Rap Battle of HIS-STORY

You’ve got delusions of “C”-Rappin’ with #Eminem on #MTV

Your #TedNugents #Nugents would be on display for the Whole World Wide Web to SEE

Maybe you should hurry up and run back home to your M-O-M-M-IEEE!!!

I KNOW, who I AM

I AM, Number ONE

I don’t fit into your “Master Plan”

I AM, Number ONE

(It’s better to be Pissed-OFF than Pissed-ON “little man”)

I KNOW, who I AM

I AM, Number ONE

Hey Ho “SkeptiCowards©”

Is THAT all you’ve GOT?

You remind me of Ike TURNER

Was THAT your best SHOT?

Maybe ya betta stay at HOME

Sittin’ on the POT

Until you solve that PROBLEM

That requires too much THOUGHT

Like how to answer a QUESTION

Or “Where are your FACTS?”

Because you’ve been runnin’, hidin’, and DODGIN”

After you had another Faux Tu-Quoque ATTACK

All I hear from some of youse MOUTHS

Is Quack-ack-ack-ack-ACK

I thought Billy Joel warned YOU

Bout having a Heart Attack-ack-ack-ack-ACK

This is the “Home of the BRAVE”

(Maybe you should “Learn to SWIM”)

Before you start to Hack-ack-ack-ack-ACK

George Washington cut down a Cherry TREE

(Was THAT your Cherry-Pickin’ Tree? Whoa is ME!)

They say Lizzie Borden gave her mother 40 Whack-ack-ack-ack-ACKS

• I KNOW, who I AM

I AM, Number ONE

I don’t fit into your “Master Plan” ?

I AM, who I AM

I KNOW, who I AM

I AM, Number ONE

I KNOW who I AM

I AM Number ONE

Oh NO! Here comes Peter AGAIN – FLEA!!

Did he really rob himself to pay PAUL?

I heard him mumble something ’bout CaliCultication

And another Brick in the WALL

Mary told me he denied himself THRICE

As he was trying to Break Down The WALLS

If we don’t hurry up we’ll be LATE

For the World Premiere of the New MONSTER’s BALLS

Lil’ Johnny’s got a DATE

With the New Kids Down the HALL

And we’re going to the “Stones'” CONCERT

We’re gonna throw some BACK

So ya betta’ duck YA’LL

Here’s comes some more Roberta FLACK

Now that wall doesn’t seem so TALL

They’re comin’ to America’s CALL

Now, why is #CMPunk a #Heyman Guy PAUL?

• I KNOW, who I AM

I AM, Number ONE

Your “Master Plan” is like a yellowed Bed Pan

I AM, who I AM

I KNOW, who I AM

I AM, Number ONE

I KNOW who I AM

I AM Number ONE

Oh NO !

Anyone heard ’bout what happens when Birds ATTACK?

Look Out BELOW!

The sky changes from 50 shades of Grey

To #Metallica #FadeToBLACK

Rockapocalypse !!!

@TheRock said #ItDoesntMatter

What BBC Spam-o-rama

the “Riddler” wannabe

or Blatherskitewicz SAID

Your #DavidBowie 15 seconds of #Fame

has you #BurningDownTheHouse with your #TalkingHEADS

#Jabroni

Critics and Cynics

“The Skeptics™”

I thought you had Grapefruits

like @VinceMcMahon

But all you’ve got is #FruityPebbles

like @JohnCena

I feel so ROBbed Van DAMN !!!

what ! What !! WHAT !!!

is your GOAL?

You wouldn’t touch”IT”with a #ZZTop #TenFootPOLE

Your #Garbage smells #Special

#NineInchNails #HeadLikeAHole ?

Your Salem Witch Trial

#HistoryOfTheWorld PartI

was FROZEN

BORING

#PinkFloyd #ComfortablyNUMB

Like a #SuperTramp

You #HideInYourShell

You Blatherskite without a CLUE

Who the … are YOU ?

#WhoAreYou ?

#TheWHO ?

#WeKnowThatTheHypnotizedNeverLie
http://youtu.be/zYMD_W_r3Fg #BloodyWellRight you SEE ?
http://t.co/IY53fEpnBu
You talk about “deconstruction”

#AWESOME

@TripleH #TimeToPlayTheGame ?

#MMA ?

#UFC ?

#WWE ?

Like #KidRock sings

“And this is for the Questions that don’t have any Answers”

U can’t out “C”-Rap ME

Yo #Eminem

May I Have Your Attention PLEASE ?

This ain’t about ME

It’s about the F-D-A
redd.it/1h2slh
and Dr. Stanislaw Rajmund #BURZYNSKI

• I KNOW, who I AM

I AM, Number ONE

I KNOW, who I AM

I AM, who I AM

I KNOW, who I AM

I AM, Number ONE

I KNOW who I AM

I AM Number ONE

Doctor David H. Gorski: This Is Your Life (Brought to you by “Mud” Life – For that refreshing MudBeer taste)

“The Skeptics” Theme Song
https://stanislawrajmundburzynski.wordpress.com/2013/05/25/the-skeptics-theme-song/
“The Skeptics”

“The Metastasis of MisDisInformation”

“The Doctor of Dissimulation”

THIS is your Life:
http://www.med.wayne.edu/surgery/faculty/DGorski.html
Dr. Gorski, from your bio we know the following:

Title: “Assistant Professor of Surgery”

Specialty: Breast surgery, surgical oncology

In Practice Since: 1999

Patient Appointment Scheduling: Accepts Children: No

Dr. Gorski:

Is your specialty “Brainstem Glioma, inoperable tumor is of high-grade pathology (HBSG), anaplastic astrocytoma, anaplastic HBSG, glioblastoma(s), recurrent diffuse intrinsic glioblastomas and anaplastic astrocytomas of the brainstem, diffuse intrinsic tumors, recurrence, recurrent and progressive tumors in children aged <4y, children less than 4 years old with inoperable brain stem gliomas, high-grade, recurrent and progressive brain stem glioma, high-grade, recurrent, and recurrent and progressive DBSG, brain tumors, Treatment of diffuse, intrinsic brainstem glioma in children"?

No

Is your specialty “recurrent diffuse intrinsic brain stem glioma”?

No

Is your specialty “incurable recurrent and progressive multicentric glioma”?

No

Is your specialty “pilocytic astrocytoma, low-grade astrocytoma, astrocytoma grade 2, DBSG, low- grade astrocytoma in children”?

No

Is your specialty “visual pathway glioma”

No

Is your specialty “recurrent disease or high risk”

No

Is your specialty “high-risk pediatric patients with primitive neuroectodermal tumors”?

No

Dr. Gorski, I think we have a pattern developing here, ya know?

Dr. Gorski, why should anyone care what your biased opinion of Dr. Burzynski is, ya know?

I don’t know

No … No, No, I mean … I have a blog
(http://www.scienceblogs.com/Insolence)

Dr. Gorski, moving on

According to your bio you have been a co-author; though as some of “The Skeptics” might point out, NOT the firstly named author, on:
http://cancerbiologyprogram.med.wayne.edu/faculty/gorski.php
Selected Publications:

1. Chen Y, Leal AD, Patel S, Gorski DH

The homeobox gene GAX activates p21WAF1/CIP1 expression in vascular endothelial cells through direct interaction with upstream AT-rich sequences

J Biol Chem. 2007 Jan 5;282(1):507-17. PMCID: PMC1865102

2. Chen Y, Gorski DH

Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5.

Blood. 2008;111(3):1217-26. PMCID: PMC2214763

3. Chen Y, Banda M, Speyer CL, Smith JS, Rabson AB, Gorski DH

Regulation of the expression and activity of the antiangiogenic homeobox gene GAX/MEOX2 by ZEB2 and microRNA-221.

Mol Cell Biol. 2010;30(15):3902-13. PMCID: PMC2916411

4. Chen Y, Rabson AB, Gorski DH

MEOX2 regulates nuclear factor-kappaB activity in vascular endothelial cells through interactions with p65 and IkappaBbeta.

Cardiovasc Res. 2010;87(4):723-31. PMCID: PMC2920806

5. Speyer CL, Smith JS, Banda M, Devries JA, Mekani T, Gorski DH

Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.

Breast Cancer Res Treat. 2011 Jun 17. [Epub ahead of print]

Dr. Gorski, why should anyone care what your biased opinion of Dr. Burzynski is, based on your specialty being breast cancer, ya know?

I don’t know

No … No, No, No, I mean … I have a blog
(http://www.sciencebasedmedicine.org)

Dr. Gorski, Dr. Linus Pauling, winner of two (2) Nobel Prizes; including one (1) in his “specialty” of chemistry, was of the “opinion” that quasicrystals did NOT exist

Professor Daniel Shechtman proved Dr. Pauling (“There is no such thing as quasicrystals, only quasi- scientists.”) wrong, and won a Nobel Prize in that same field of “specialty,” chemistry

Dr. Gorski, have you won a Nobel Prize, and why should anyone care what your biased opinion of Dr. Burzynski is, ya know?

I don’t know

No … No, No, No, No, I mean … I have blogs
(http://www.scienceblogs.com/Insolence)
(http://www.sciencebasedmedicine.org)

Dr. Gorski, where is YOUR antineoplaston clinical study?

� � � � � � � � � � � � �
Burzynski – The Antineoplaston Randomized Japan Phase II Clinical Trial Study:
https://stanislawrajmundburzynski.wordpress.com/2013/03/28/burzynski-the-antineoplaston-randomized-japan-phase-ii-clinical-trial-study
� � � � � � � � � � � � �
Review Article: Antineoplastons:
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/review-article-antineoplastons
� � � � � � � � � � � � �
Burzynski updates Scientific Publications page:
https://stanislawrajmundburzynski.wordpress.com/2013/03/12/burzynski-updates-scientific-publications-page
� � � � � � � � � � � � �
Stanislaw Rajmund Burzynski Publications:
https://stanislawrajmundburzynski.wordpress.com/2013/03/16/stanislaw-rajmund-burzynski-publications
� � � � � � � � � � � � �
Burzynski: China antineoplaston publications:
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-china-antineoplaston-publications
� � � � � � � � � � � � �
Burzynski and China / Taiwan, ROC:
https://stanislawrajmundburzynski.wordpress.com/2013/02/18/burzynski-china-taiwan-roc
� � � � � � � � � � � � �
Burzynski, Ming-Cheng Liau, and Gi-Ming Lai:
https://stanislawrajmundburzynski.wordpress.com/2013/02/24/burzynski-ming-cheng-liau-gi-ming-lai
� � � � � � � � � � � � �
Burzynski, China, and Dvorit D. Samid:
https://stanislawrajmundburzynski.wordpress.com/2013/02/21/burzynski-china-dvorit-d-samid
� � � � � � � � � � � � �
Burzynski and Taiwan, ROC:
https://stanislawrajmundburzynski.wordpress.com/2013/02/20/burzynski-taiwan-roc
� � � � � � � � � � � � �
Burzynski, Hideaki Tsuda (Japan), and the p53 gene
https://stanislawrajmundburzynski.wordpress.com/2013/03/04/burzynski-hitoshi-tsuda-japan-and-the-p53-gene
� � � � � � � � � � � � �
Burzynski: Japan antineoplaston publications:
https://stanislawrajmundburzynski.wordpress.com/2013/02/19/burzynski-japan
� � � � � � � � � � � � �
Burzynski: Egypt antineoplaston publications:
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-egypt-antineoplaston-publication
� � � � � � � � � � � � �
Antineoplastons, which were first described by Burzynski:
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/antineoplastons-which-were-first-described-by-burzynski
� � � � � � � � � � � � �
Burzynski: Russia antineoplaston publications:
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-russia-antineoplaston-publications
� � � � � � � � � � � � �
Burzynski: South Korea antineoplaston publications:
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-south-korea-antineoplaston-publications
� � � � � � � � � � � � �
Burzynski: Poland antineoplaston publications:
https://stanislawrajmundburzynski.wordpress.com/2013/04/25/burzynski-poland-antineoplaston-publications

Dr. Gorski, one last question

In the spirit of Dr. Pauling, do you believe there is no such thing as Skeptics, only SkeptiCowards©?
http://redd.it/1f6meh
Paging Doctor David H. Gorski, Paging Doctor David H. Gorski: There’s Mud in your Ears … Doktor Gorski?
https://stanislawrajmundburzynski.wordpress.com/2013/05/28/paging-doctor-david-h-gorski-paging-doctor-david-h-gorski-theres-mud-in-your-ears-doktor-gorski/

Shall We Play A Game? “The Skeptics” (SkeptiCowards) vs. “The Skeptics'” Critics #Burzynski The 1st ever “LIE OFF”

It is the first ever “LIE OFF”

RULES:

1. One (1) “LIE” per Tweet (or blog comment)

2. You may use the same link to refer to additional “LIES” (One (1) at a time)

3. The “LIE” MUST be supported by “FACTS” (Citation(s), Reference(s), and / or Link(s)) – I realize that having to rely on “FACTS” may put many of “The Skeptics” at a perceived “disadvantage,” since many of them are so used to getting away with unsubstantiated vitriolic comments (Example: See
http://www.forbes.com/sites/peterlipson/2013/04/19/a-film-producer-a-cancer-doctor-and-their-critics)

4. The “alleged” “LIAR” may contest their exalted position (One (1) issue at a time)

5. You may have to pull an Anthony Jeselnik, and “Defend Your Tweet” (One (1) issue at a time)

6. Score will be kept of the “LIES

7. All “LIES” are binding and are the responsibility of the “LIAR” (This contest is in no way affiliated with Anthony Jeselnik or Comedy Central … maybe … that could be a “LIE“)

https://twitter.com/FauxSkeptic/status/337362207258066947

https://mobile.twitter.com/FauxSkeptic/statuses/337362207258066947

https://twitter.com/AllUrBaseRBe2us/status/337366091108057088

https://mobile.twitter.com/AllUrBaseRBe2us/statuses/337366091108057088

https://twitter.com/FauxSkeptic/status/337379052400803842

https://mobile.twitter.com/FauxSkeptic/statuses/337379052400803842

*The small print is important. This is NOT a “Pissing” Contest. Pissers will be perfunctorily penalized and Pissed OFF (Rules are subject to being changed arbitrarily and capriciously; something “The Skeptics” have an intimately familiar relationship with)

Have a Nice Day

Remember kids, this WikipediAin’t The People’s Court;” (Doug Llewelyn is NOT looking over your shoulder) you CAN take “The LIE” into your own hands

So don’t get “Pissed OFF,” get the “Lie Off

LIE

“The Skeptics” (SkeptiCowards)

1. 5/23/2013 – Dr. David H. Gorski
2. 5/23/2013 – Dr. David H. Gorski
3. 5/24/2013 – Guy Chapman
4. 5/25/2013 – Guy Chapman
5. 5/29/2013 – dougal445

The Skeptics” Critics

*

1. David Gorski (@gorskon) tweeted at 12:44pm – 30 Mar 13:

NO, Dr. Gorski, you have NOT “deconstructed his “evidence” in depth before”
Burzynski: Cancer Is Serious Business (Part I) consists of the documentary; as well as the documents on the movie web-site, which you have NOT “deconstructed … in depth before”
David Gorski (@gorskon)
5/23/13, 9:32 AM
@FauxSkeptic No need to defend my Tweet. The defense is in the link. http://www.sciencebasedmedicine.org/index.php/stanislaw-burzynski-bad-medicine-a-bad-movie
2013-05-23 16:45:18
FauxSkeptic:
@gorskon
Ignoring:

Documents/BurzynskiTriesToExposeNCI.pdf
is NOT:”deconstructed his”evidence”in depth…”
http://redd.it/1ewce0
#Burzynski

2.
https://mobile.twitter.com/gorskon/status/325715182045245440

AllUrBaseRbelong2us (@AllUrBaseRBe2us)
5/23/13, 8:15 PM
AnthonyJeselnik☆
@gorskon🚫
U tweeted4/20/13
http://po.st/69JIvR
#Burzynski
http://redd.it/1ewce0
Defend tweet😅

http://redd.it/1dq3nd

3. FauxSkeptic (@FauxSkeptic)
5/24/13, 12:33 PM
☆AnthonyJeselnik:☆
🚫”The Skeptics” @vGuyUK,🚫
you blahgged at:📄
http://redd.it/1dpsj6
Defend your twit:😅

http://redd.it/1dpsj6

4. ☆AnthonyJeselnik:☆
🚫SceptivGuyChapmanUK,🚫
you blahgged at:📄
redd.it/1dr2xg
Defend your twit:😅

http://t.co/YRd0oSzL9l

5. @dougal445 tweeted at 1:16am-19 Apr 13:
http://po.st/0EpLAz
Defend Your Tweet:
http://redd.it/1du07r
#Burzynski

http://po.st/BBoHhh